The threat of the appearance of myocarditis -; or inflammation of the central muscle -; is seven times higher with a COVID-19 infection than with the COVID-19 vaccine, according to a recent study by Penn State College of Medicine scientists. Patients with myocarditis may experience chest pain, shortness of breath, or abnormal central heartbeat. In severe cases, inflammation can lead to center failure and death.
Our findings show that the threat of myocarditis becoming inflamed with COVID-19 is much greater than getting the vaccine. In the future, it will be to monitor possible long-term effects on those who spread myocarditis. “
Myocarditis is one of the headaches of SARS-CoV-2 infection. Although vaccines have been shown to reduce severe COVID-19 symptoms, heart headaches have been linked to COVID-19 mRNA vaccination; especially myocarditis in adolescents. However, the relative threat of myocarditis due to vaccines and infections is not well characterized in giant studies.
The Penn State team conducted the largest study to date on the risk of myocarditis as a result of having the coronavirus rather than inflammation after COVID-19 vaccination. The researchers compared patients with COVID-19; vaccinated and unvaccinated – ; to those who do not have the virus. They found that the risk of myocarditis is 15 times higher in COVID-19 patients, regardless of vaccination status, compared to other people who did not contract the virus.
The researchers then compared the rates of myocarditis in those who received the vaccines with those who did not. According to the results, rates of myocarditis in other people vaccinated against COVID-19 were only twice as high as in other unvaccinated people.
Based on all the findings, the researchers concluded that the threat of myocarditis due to COVID-19 is seven times greater than the threat from vaccines.
Researchers conducted a systematic review and meta-analysis of 22 internationally published studies from December 2019 to May 2022. The studies included almost 58 million people who reported central headaches and belonged to one of two groups: 55. 5 million who were vaccinated instead of COVID-19 compared to those who were not vaccinated (vaccination group), and 2. 5 million who became infected with the virus compared to those who did not contract the virus (COVID-19 group).
In the vaccination group, researchers separately compared the risk of myocarditis for COVID-19 vaccines, adding mRNA (Pfizer, Moderna), Novavax, AstraZeneca, and Johnson and Johnson. The median age of the population examined was 49 years; 49 per cent were men; and median follow-up time after COVID-19 infection or vaccination was 28 days.
The researchers found that among those diagnosed with myocarditis after receiving the vaccine or having COVID-19, the majority (61%) were men. % died.
“COVID-19 infection and related vaccines pose a threat of myocarditis. However, the relative threat of central inflammation induced by COVID-19 infection is particularly greater than the threat posed by vaccines,” said Dr. Paddy Ssentongo, a resident physician in the Department of Medicine at Penn State Health Milton S. Hershey Medical Center and leader of the study. “We hope that our findings will help alleviate vaccine hesitancy and increase vaccine uptake. “
Surya Reddy of Osmania Medical College contributed to this research.
State of Pennsylvania
Voleti, N. , et al. (2022) Myocarditis in SARS-CoV-2 infection compared with COVID-19 vaccination: a systematic review and meta-analysis. Frontiers in cardiovasculaire. doi. org/10. 3389/fcvm. 2022. 951314 medicine.
News-Medical. net – An AZoNetwork website
Owned and operated through AZoNetwork, © 2000-2022